Emodan Special Precautions

Hypersensitivity reactions have been reported in patients who have exhibited hypersensitivity to other selective 5-HT₃ receptor antagonists.
As Ondansetron is known to increase large bowel transit time, patients with signs of sub-acute intestinal obstruction should be monitored following administration.
Patients with severe hepatic impairment.
In psychomotor testing, Ondansetron does not impair performance nor cause sedation.
Use in Children: The safety in children has not been established sufficiently. Experience of the use of ondansetron in children is limited.
Use in the Elderly: Dosage adjustment is not needed in patients over the age of 65. Prevention of nausea and vomiting in elderly patients was no different than in younger age-groups.
Use in pregnancy & lactation: There are no adequate and controlled studies to date using Ondansetron in pregnant women. Reproduction studies have been performed in pregnant rats and rabbits at I.V. doses up to 4 mg/kg per day and have revealed no evidence of impaired fertility or harm to the fetus due to Ondansetron. Because animal reproduction studies are not always predictive of human response, this drug should be used during pregnancy only if clearly needed.
Animal tests (with rats) have shown that Ondansetron is excreted in the breast milk. It is therefore recommended that mothers receiving this drug should not breast-feed their babies.